A comprehensive view of eli lilly & co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Lilly’s Retevmo selpercatinib in 40 mg, 80 mg capsules receives accelerated clearance by FDA to treat adult patients with advanced or metastatic solid tumors
Published: September 28, 2022 by PBR, Pharmaceutical Business Review
US EEOC files age discrimination lawsuit against Eli Lilly, alleging Lilly snubbed older workers for sales representative positions from April 2017 to 2021; EEOC alleges Lilly changed hiring practices in 2017 to add more millennials to workforce
Published: September 28, 2022 by FiercePharma
UBS upgrades Eli Lilly to buy from neutral, as company starts submitting marketing application for late-stage Alzheimer’s medication Donanemab, which could be 'biggest drug ever' and 'highest potential late-stage Alzheimer’s asset'
Published: September 22, 2022 by Finbold
Eli Lilly prepared to fully supply its recently approved injectable diabetes drug Mounjaro tirzepatide in the US, with drug tracking near the highest end of demand expectations; sales of Mounjaro could reach US$4.9B by 2026 reports Evaluate Vantage
Published: September 15, 2022 by FiercePharma
Use of Lilly’s bamlanivimab-etesevimab, Regeneron’s casirivimab-imdevimab COVID-19 antibodies 'widespread' after FDA ban, potentially costing US over US$70.0M; hospitals, health systems administered over158,000 doses of these mAbs in early 2022: JAMA
Published: September 02, 2022 by FiercePharma

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count